RxDoctor Payments Data

Rebecca Pettigrew, PA

Physician Assistant · Pinehurst, NCNPI 1144779331

Payments from drug & device makers

$13,582in general payments, 2019–2025

Across 529 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Inspire Medical Systems, Inc.$2K
  • AstraZeneca$2K
  • Actelion Pharmaceuticals US, Inc.$926
  • Sanofi$763
  • Grifols USA, LLC$762
  • plus $6K from 34 others

What the payments were for

  • Travel & lodging$7015%
  • Food & beverage$12,78194%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,582 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$92,473
Medicare patients
310
Services billed
2,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter211$162,048
OfevNintedanib Esylate12$156,004
Dupixent PenDupilumab34$134,758
Breo ElliptaFluticasone/Vilanterol124$68,826
Dupixent SyringeDupilumab13$47,044
Arnuity ElliptaFluticasone Furoate141$38,069
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$17,097
Pirfenidone23$16,427
Ambrisentan11$16,099
SymbicortBudesonide/Formoterol Fumarate49$15,705
Spiriva RespimatTiotropium Bromide14$14,198
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$11,567
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$10,346
Combivent RespimatIpratropium/Albuterol Sulfate11$5,063
BreynaBudesonide/Formoterol Fumarate26$4,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta$1,819$283,925509 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$575$175,26537 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,558$32,80277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Pinehurst

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →